What are evidence-based therapeutic doses of l-arginine for erectile dysfunction and heart disease?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Randomized trials and meta-analyses place the evidence-based therapeutic dosing window for oral L‑arginine in erectile dysfunction (ED) roughly between 1.5 and 6 grams per day, with many positive studies clustered in the 2–5 g/day range and one controlled trial testing 6 g/day for three months [1] [2]. For cardiovascular indications the data are more heterogeneous: some studies of angina, heart failure and endothelial function used similar gram‑level daily doses, but safety signals—especially after recent myocardial infarction—mean dosing cannot be recommended universally without clinician oversight [3] [4] [5].
1. How the clinical evidence defines “therapeutic dose” for erectile dysfunction
Systematic review and randomized trials show a consistent signal that arginine supplementation improves mild-to-moderate ED at gram-level daily doses: a meta-analysis found benefit across studies using 1,500–5,000 mg/day (1.5–5 g/day) [1], while a well‑controlled multicenter randomized trial tested a relatively high daily oral dose of 6 g/day for three months and reported significant improvements on validated erectile function measures compared with placebo [2] [6]. Smaller crossover and combination trials also document improvements at doses of about 2–5 g/day or when 2.5 g/day was combined with low‑dose tadalafil [7] [8].
2. Practical interpretation: what clinicians and reviews commonly report
Clinical summaries and consumer health sources typically present a pragmatic starting range of about 2 g/day and note effective dosing that has been studied from roughly 1.5 up to 5 g/day, with some trials using 6 g/day for limited periods [9] [1] [2]. Authorities also emphasize that arginine is not an on‑demand ED drug like PDE‑5 inhibitors but a daily supplement whose benefit accrues over weeks to months in trials [10] [11].
3. Cardiovascular use: dose ranges and mixed outcomes
Investigations of arginine in cardiovascular disease—angina, heart failure, endothelial dysfunction—have used similarly variable oral doses in gram quantities, and some small trials report improved exercise capacity or endothelial markers [3] [10]. However, the cardiovascular literature is mixed and context‑dependent: certain studies suggest benefits for endothelial function, while others show no improvement or even potential harm when started after an acute coronary event [3] [4].
4. Safety limits and important contraindications that shape “therapeutic” choices
Major clinic‑facing resources caution that arginine can alter blood pressure, blood sugar, and bleeding risk, interact with nitrates and some diabetes and antihypertensive drugs, and has been associated with adverse outcomes if taken after recent heart attack—warnings that force individualized dosing and clinician involvement [10] [5] [4]. These safety concerns are the pragmatic reason many providers favor lower trial doses (≈2 g/day) or combination regimens under supervision rather than routine use of higher doses like 6 g/day [9] [7].
5. Evidence gaps, competing interpretations and a conservative clinical takeaway
Evidence supports that daily oral L‑arginine in the 1.5–5 g/day range can improve mild–moderate ED in some patients, and a 6 g/day regimen showed benefit in a specific three‑month trial, but heterogeneity in doses, small sample sizes and safety caveats—particularly for people with recent cardiac events—mean universal dosing recommendations are premature [1] [2] [4]. For cardiovascular disease there are promising mechanistic and small‑trial signals using gram‑level dosing, but mixed outcomes and safety alerts require individualized clinician assessment before use [3] [10].